Interventional Cardiology Market Size, Share, Opportunities, And Trends By Device Type (Stents, Catheters, Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloons, Others), By Application (Coronary Artery Disease, Heart Valve Disease, Peripheral Vascular Disease, Structural Heart Disease), By End-User (Hospitals and Clinics, Ambulatory Surgery Centers), And Geography - Forecasts From 2025 To 2030

The interventional cardiology market is projected to grow at a CAGR of 6.48% during the forecast period.

Interventional cardiology is a minimally invasive procedure that utilizes catheters to repair damaged or weakened vessels, narrowed arteries, or other affected parts of the heart structure. Catheters are medical devices consisting of thin tubes that can be inserted into the body to serve a broad range of functions. Interventional cardiology also helps to avoid surgery with treatments like angioplasty and valve repair or replacement. The interventional cardiology market is expected to show robust during the forecast period owing to the rising adoption of minimally invasive procedures and rising incidences of cardiovascular diseases. As per data by WHO, cardiovascular diseases are the leading cause of death globally with an estimated 17.9 million people dying of CVDs in 2016. Technological advancements in interventional cardiology devices will also boost the market for interventional cardiology during the forecast period. However, stringent regulatory requirements for the approval of interventional cardiology devices might restrain the growth of the interventional cardiology market during the given time frame.

DRIVERS
Increasing prevalence of cardiovascular diseases.
Technological advancements in interventional cardiology devices.
Increasing health expenditure worldwide.

RESTRAINTS
Regulations regarding approval of interventional cardiology devices.
High cost of interventional cardiology procedures in developing and underdeveloped economies.

INDUSTRY UPDATE
In March 2019, Medtronic entered into an agreement with the Medical University of South Carolina with the aim of helping patients by delivering the best treatments at a lower cost. In addition, this is considered as a value-based agreement in order to help identify and diagnose the patients sooner.
In April 2018, BIOTRONIK US and Aziyo announced a strategic agreement allowing BIOTRONIK to distribute Aziyo’s CanGaroo® extracellular matrix (ECM) cardiovascular implantable electronic device (CIED) envelopes in the United States.

The major players profiled in the global interventional cardiology market include Medtronic, Stryker, Abbott, B. Braun Melsungen AG, Boston Scientific Corporation, Cordis (A Cardinal Health Company), Edwards Lifesciences Corporation, GE Healthcare, Biosensors International Group, Ltd., and Biotronik, Inc. among others.

Segmentation

The global interventional cardiology market has been analyzed through the following segments:

By Device Type
Stents
Catheters
Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloons
Others

By Application
Coronary Artery Disease
Heart Valve Disease
Peripheral Vascular Disease
Structural Heart Disease

By End-User
Hospitals and Clinics
Ambulatory Surgery Centers

By Geography

North America
USA
Canada
Mexico

South America
Brazil
Argentina
Others

Europe
United Kingdom
Germany
France
Others

Middle East and Africa
Saudi Arabia
UAE
Israel
Others

Asia Pacific
China
India
Australia
South Korea
Others

1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. KEY FINDINGS
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. GLOBAL INTERVENTIONAL CARDIOLOGY MARKET BY DEVICE TYPE
5.1. Stents
5.2. Catheters
5.3. Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloons
5.4. Others
6. GLOBAL INTERVENTIONAL CARDIOLOGY MARKET BY APPLICATION
6.1. Coronary Artery Disease
6.2. Heart Valve Disease
6.3. Peripheral Vascular Disease
6.4. Structural Heart Disease
7. GLOBAL INTERVENTIONAL CARDIOLOGY MARKET BY END-USER
7.1. Hospitals And Clinics
7.2. Ambulatory Surgery Centers
8. GLOBAL INTERVENTIONAL CARDIOLOGY MARKET BY GEOGRAPHY
8.1. North America
8.1.1. USA
8.1.2. Canada
8.1.3. Mexico
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. United Kingdom
8.3.2. Germany
8.3.3. France
8.3.4. Others
8.4. Middle East and Africa
8.4.1. Saudi Arabia
8.4.2. UAE
8.4.3. Israel
8.4.4. Others
8.5. Asia Pacific
8.5.1. China
8.5.2. India
8.5.3. Australia
8.5.4. South Korea
8.5.5. Others
9. COMPETITIVE INTELLIGENCE
9.1. Competitive Benchmarking and Analysis
9.2. Recent Investments and Deals
9.3. Strategies of Key Players
10. COMPANY PROFILES
10.1. Medtronic
10.2. Stryker
10.3. Abbott
10.4. B. Braun Melsungen AG
10.5. Boston Scientific Corporation
10.6. Cordis (A Cardinal Health Company)
10.7. Edwards Lifesciences Corporation
10.8. GE Healthcare
10.9. Biosensors International Group, Ltd.
10.10. Biotronik, Inc.
LIST OF FIGURES
LIST OF TABLES

Medtronic
Stryker
Abbott
B. Braun Melsungen AG
Boston Scientific Corporation
Cordis (A Cardinal Health Company)
Edwards Lifesciences Corporation
GE Healthcare
Biosensors International Group, Ltd.
Biotronik, Inc.